Resmed 1QFY15 earnings summary
Scott Power
Morgans
Resmed 1QFY15 underlying earnings were in line with expectations, with another quarter of double-digit sales growth, underpinned by strong US flow generator uptake and continued strength in masks beating market growth rates. While ROW sales continue to be impacted by disappointing SERVE-HF trial results, the impact remains ring-fenced and failed to detract from market-tracking growth across product categories and robust sales in APAC. We remain confident 1Q marks the earnings nadir, with momentum increase throughout the year as the pricing environment is stable, cost-out initiatives take hold, FX headwinds abate and the value-enhancing healthcare informatics platform continues to drive channel efficiencies. (RMD, Add, Price Target A$8.86)
Never miss an update
Enjoy this wire? Hit the ‘like’ button to let us know.
Stay up to date with my current content by
following me below and you’ll be notified every time I post a wire
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media.
I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these sectors, which help with identification of key trends and developments.
1 stock mentioned
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Scott Power
Senior Analyst
Morgans
Senior Analyst at Morgans covering healthcare, life science, telecommunications, technology and media. I've spent the last twenty years investing in and researching emerging companies and have developed a wide network of contacts across these...
Expertise
No areas of expertise
Comments
Comments
Sign In or Join Free to comment